CIK 0001579428 · Large accelerated filer
Axsome Therapeutics, Inc.
Sign in to watch- Ticker
- AXSM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 454241907
- Phone
- (212) 332-3241
- Business address
- ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK, NY, 10007
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,086,500
- in 1 filing, $2.1M under 10b5-1 plans
Net −$2,086,500. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-22 | Jacobson Mark L. Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 35,378 | ||
| 2025-09-16 | Jacobson Mark L. Chief Operating Officer | Sale 10b5-1 | −5,783 | $116.19 | $672K | 0 |
| 2025-09-16 | Jacobson Mark L. Chief Operating Officer | Option exercise 10b5-1 | +25,000 | $4.95 | $124K | 25,000 |
| 2025-09-16 | Jacobson Mark L. Chief Operating Officer | Option exercise 10b5-1 | +15,000 | $4.85 | $73K | 40,000 |
| 2025-09-16 | Jacobson Mark L. Chief Operating Officer | Sale 10b5-1 | −40,000 | $114.23 | $4.6M | 0 |
| 2025-09-16 | Jacobson Mark L. Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | 0 | ||
| 2025-09-16 | Jacobson Mark L. Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 0 | ||
| 2025-09-16 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise 10b5-1 | +19,719 | $8.02 | $158K | 26,948 |
| 2025-09-16 | TABUTEAU HERRIOT Chief Executive Officer | Sale 10b5-1 | −19,719 | $114.19 | $2.3M | 7,229 |
| 2025-09-16 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −19,719 | 461,120 | ||
| 2025-09-15 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise 10b5-1 | +15,254 | $8.02 | $122K | 22,483 |
| 2025-09-15 | TABUTEAU HERRIOT Chief Executive Officer | Sale 10b5-1 | −15,254 | $117.37 | $1.8M | 7,229 |
| 2025-09-15 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,254 | 480,839 | ||
| 2025-09-12 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise 10b5-1 | +27,907 | $8.02 | $224K | 35,136 |
| 2025-09-12 | TABUTEAU HERRIOT Chief Executive Officer | Sale 10b5-1 | −27,907 | $118.96 | $3.3M | 7,229 |
| 2025-09-12 | TABUTEAU HERRIOT Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,907 | 496,093 | ||
| 2025-09-08 | Coleman Mark Director | Purchase | +800 | $127.20 | $102K | 47,437 |
| 2025-09-08 | Coleman Mark Director | Purchase | +287 | $127.30 | $37K | 47,724 |
| 2025-09-08 | Coleman Mark Director | Purchase | +488 | $127.40 | $62K | 48,212 |
| 2025-09-05 | Saad Mark E Director | Option exercise 10b5-1 | +9,127 | $9.00 | $82K | 19,129 |
Page 7 of 22 · 422 trades